PTO/SB/96 (01-08)
Approved for use through 02/29/2008 0M6 0505-1001
U.S. Patient and Tademark Office; U.S. DEPARTISHENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number

SIAI	EMENT UNDER 37 CFR 3.73	(b)
Applicant/Patent Owner: WEX Pharmaceuticals In-	Ç	
Application No /Patent No : 6,780,866	Filed/Issue Date: August 24	, 2004
Entitled: ANALGESIC COMPOSITION AND METHO	DD	
WEX Pharmaceuticals Inc. (Name of Assignee)		dion, partnership, university government agency, etc.)
states that it is: 1. $\boxed{\gamma}$ the assignee of the entire right, title, and in	nterest; or	
 an assignee of less than the entire right, til (The extent (by percentage) of its ownersh 		
in the patent application/patent identified above b	by virtue of either:	
A A assignment from the inventor(s) of the p in the United States Patent and Trademark thereof is attached OR	patent application/patent identified Office at Reel <u>017303</u> , Fr	above. The assignment was recorded ame 0413 , or for which a copy
B A chain of title from the inventor(s), of the p	patent application/patent identified	above, to the current assignee as follows:
1 From:The document was recorded in the Reel, Frame	To:To: United States Patent and Tradem, or for which a cop	ark Office at by thereof is attached
2 From: The document was recorded in the Reel, Frame	To: United States Patent and Tradem , or for which a c	ark Office at opp thereof is attached
3 From:	To:	
The document was recorded in the Reel, Frame	United States Patent and Tradem	ark Office at copy thereof is attached
Additional documents in the chain of titl	e are listed on a supplemental she	eet
As required by 37 CFR 3 73(b)(1)(i), the docassignee was, or concurrently is being, submitted		
[NOTE: A separate copy (i e, a true copy of Division in accordance with 37 CFR Par 302 08]		
The undersigned (whose title is supplied below) i	s authorized to act on behalf of th	e assignee
	<u> </u>	March 11 2008
Signature		March 11 2008 Date 604-676-7914
Bin Huang		
Printed or Typed N	lame	Telephone Number
CEO, WEX Pharmaceu	ticals Inc.	

This collection of information is required by 37 CFR 3 73(b) The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentially is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to take 12 minutes to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the including cases. Any commants on the amount of time you require to complete this form ander suggestions for reducing this burden, should be sent to the Chief Information Officer. US Patient and Trademark Office, US Department of Commerce, PO Box 1450, Abswarding. VA 2231-314-350, DN ORT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450,